Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms Flutafuranol F 18, AZD-4694, NAV-4694 + [2] |
Target |
Mechanism APP modulators(Beta amyloid A4 protein modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H11FN2O2 |
InChIKeyMYNQXTDIPMCJCR-HUYCHCPVSA-N |
CAS Registry1211333-21-9 |
Start Date23 Nov 2021 |
Sponsor / Collaborator |
Start Date01 Jun 2013 |
Sponsor / Collaborator |
Start Date01 Mar 2013 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | US | 01 Jun 2013 | |
Mild cognitive disorder | Phase 2 | US | 01 Mar 2013 | |
Cognitive Dysfunction | Phase 2 | - | - | |
Cognitive Dysfunction | Phase 2 | - | Cerveau Technologies, Inc.Startup | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 76 | ygmiyyfnnj(boptmfijoe) = wzwkunnetc dexnzgodjv (srhentqowv, ytuumfpwaw - kzwjatkkhi) View more | - | 14 Aug 2024 | |||
Not Applicable | - | oqviowdcnp(rmgdxkvlhn) = uudpmtjvhd onsizuupri (xnokxohmnv ) | - | 01 Jul 2013 | |||
oqviowdcnp(rmgdxkvlhn) = xqqpykgdfw onsizuupri (xnokxohmnv ) |